More than two years have passed since the viral outbreak that led to the novel infectious respiratory disease COVID-19, caused by the SARS-CoV-2 coronavirus. Since then, the urgency for effective treatments resulted in unprecedented efforts to develop new vaccines and to accelerate the drug discovery pipeline, mainly through the repurposing of well-known compounds with broad antiviral effects. In particular, antiparasitic drugs historically used against human infections due to protozoa or helminth parasites have entered the main stage as a miracle cure in the fight against SARS-CoV-2. Despite having demonstrated promising anti-SARS-CoV-2 activities in vitro, conflicting results have made their translation into clinical practice more difficult than expected. Since many studies involving antiparasitic drugs are currently under investigation, the window of opportunity might be not closed yet. Here, we will review the (controversial) journey of these old antiparasitic drugs to combat the human infection caused by the novel coronavirus SARS-CoV-2.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320270 | PMC |
http://dx.doi.org/10.3390/microorganisms10071284 | DOI Listing |
Parasitol Res
January 2025
Medical Parasitology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Blastocystis, an eukaryote, inhabits the intestinal tract of humans and animals worldwide. Lactobacillus acidophilus (L. acidophilus), a probiotic, has been reported to be effective against blastocystosis.
View Article and Find Full Text PDFTurkiye Parazitol Derg
January 2025
Hatay Mustafa Kemal University Faculty of Medicine, Department of Parasitology, Hatay, Türkiye.
The study presents two imported malaria cases with a history of travel to malaria-endemic areas and replied late response to treatment. In the blood preparations of the first case, dot-shaped nucleus structures were identified in the erythrocytes, which looked different from the classical erythrocytic forms. In the SD-Pf/Pan test, bands were obtained for both P.
View Article and Find Full Text PDFTurkiye Parazitol Derg
January 2025
University of Health Sciences Türkiye, Kartal Dr. Lütfi Kırdar City Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Türkiye.
Objective: Cystic echinococcosis (CE) is a zoonotic condition that can be encountered, particularly in developing countries, and leads to significant economic losses. This study was planned to observe the treatment options, complications, in the patients we followed.
Methods: Patients aged 18 and over who were diagnosed with hydatid cyst and followed in our hospital between January 2018 and December 2023 were included in the study.
BMC Vet Res
January 2025
Materials Synthesis Laboratory, Carbon Tech Industrial Group, Carbon Tech, Tehran, Iran.
Background: Strongyle nematodes pose a major challenge in veterinary parasitology, causing significant economic losses in livestock due to resistance to conventional treatments. Current anthelmintics, like Ivermectin, often encounter resistance issues. This study aims to address these gaps by synthesizing Carbon Quantum Dots (CQDs) and Copper-Doped CQDs (Cu@CQDs) using glucose extract, and evaluating their nematicidal properties against strongyles in vitro.
View Article and Find Full Text PDFMalar J
January 2025
Department of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Background: Congenital malaria remains a significant public health challenge in Nigeria, particularly in regions with high malaria endemicity. The increased vertical transmission of malaria is partly associated with the high susceptibility of women to malaria during pregnancy. This systematic review aimed to assess the prevalence, characteristics, and treatment outcomes of congenital malaria in Nigeria.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!